Filing Details
- Accession Number:
- 0001214659-18-001631
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-27 18:00:14
- Reporting Period:
- 2018-02-23
- Accepted Time:
- 2018-02-27 18:00:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1576263 | Mirati Therapeutics Inc. | MRTX | Pharmaceutical Preparations (2834) | 462693615 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1579824 | M Charles Baum | C/O Mirati Therapeutics Inc. 9393 Towne Centre Drive, Ste 200 San Diego CA 92121 | President & Ceo | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-02-23 | 51,810 | $8.50 | 100,366 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-02-23 | 40,748 | $27.89 | 59,618 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-02-23 | 11,062 | $28.56 | 50,932 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Common Stock | Disposition | 2018-02-23 | 51,810 | $0.00 | 51,810 | $8.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
155,430 | 2020-07-16 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.
- This transaction was executed in multiple trades at prices ranging from $27.45 to $28.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $28.45 to $28.725. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 20% of the shares subject to the stock option vested and became exercisable on the Date of Grant and 20% of the shares vested on each of the 1st 2nd, 3rd and 4th anniversaries of November 12, 2012. The options expire on July 16, 2020.
- Includes 2,376 shares acquired under the ESPP Purchase on 11/30/17.